// App-Quantinova.ai

5692 : Identification of novel CDK12 inhibitors that synergize with PARP inhibition through induction of ‘BRCAness’ phenotype

Researchers

Presenter

  • Edward K. Ainscow

Principal Investigators

  • Ashwani Bahl

  • Stuart Thompson

  • Luke Flatt

  • Damien Crepin

  • Brett Stevenson

Medical Centers

  • Carrick Therapeutics, Dublin, Ireland

  • Sygnature Discovery, Nottingham, United Kingdom

Locations

  • Ireland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Ewing's sarcoma

  • Gynaecological cancer

  • Osteosarcoma

  • Sarcoma

  • Solid malignancies

Biomarkers

  • Ataxia Telangiectasia And Rad3-Related Protein

  • Nibrin

  • Breast cancer type 1 susceptibility protein

  • Cyclin dependent kinase 1

  • RAD51 Recombinase

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Olaparib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved